Introduction
The utility of D-dimer testing as a screening tool for venous thromboembolism (VTE) exclusion is uncertain in cancer patients, due to low specificity. A new fibrin assay independent of inflammation and hypercoagulability has been recently developed.
Methods
Non-anticoagulated patients with clinically suspected VTE from the FSET study (NCT02523937) had VTE diagnosed using the standard diagnostic algorithms, including a 3-month clinical follow-up. In all patients, the fibrin assay prototype (Diagnostica Stago) was performed at the time of admission. We divided the patients included in the FSET study in 3 groups: (i) history of cancer, (ii) active cancer (known or unequivocal evidence), and (iii) no cancer. We sought to evaluate the performances of the fibrin assay compared with the D-Dimer or age-adjusted D-Dimer test to exclude VTE in cancer patients.
Results
Of the 863 included patients, 83 (9.6%) had either a history of cancer (n=30) or an active cancer (known or unequivocal evidence) (n=53). The prevalence of VTE was of 3.3% and 20.7%, respectively, vs 7.6% in non-cancer patients. Patients with a history of cancer had most frequently breast cancer (40%) and genito-urinary cancer (23.3%).Of the 53 patients with active cancer (known or unequivocal evidence), 9.4% had a recurrence, and most patients had metastatic cancers (52.8%). Those patients had most frequently lung cancer (26.4 %) and breast cancer (15.1 %). Overall, 18.9% of patients with known cancer were treated with chemotherapy, 3.7% with immunotherapy and 13.2% with hormonotherapy. In the present study, 9.4% of patients with known active cancer had a high VTE probability vs 2.8% in patients without cancer. Overall, given a high VTE clinical probability score in a substantial number of cancer patients on one hand, and the DDi level most likely above the cut-off value for VTE exclusion in those with a low-to-moderate probability on the other hand, cancer patients required more often imaging to confirm or exclude VTE diagnosis, 68.7% in patients with a history of cancer or with active cancer versus 42.6% in patients without cancer, respectively. The fibrin assay specificity for VTE was highly increased compared to D-Dimer test, associated with a 100% negative predictive value [95% CI 89-100%] and [95% CI 83-100%] respectively in patients with a history of cancer or with active cancer. Fibrin assay allowed ruling out VTE in a much higher proportion of patients compared to the 500 μg/L D-Dimer cut-off / or age-adjusted D-Dimer cut-off strategy, irrespectively of clinical probability assessment: 76.7% vs 40%/60% in patients with a history of cancer, 39.6% vs 17.0%/22.6% in patients with active cancer, 76.7% vs 54.5%/60.9% in non-cancer patients.
Conclusion
The new fibrin assay demonstrated an increased specificity compared to DDi or age-adjusted cut-off strategy with excellent negative predictive value, resulting in safely excluding more than 25% VTE compared to DDi or more than 15% VTE compared to age-adjusted cut-off in patients with a history or an active cancer; thus reducing imaging testing in these patients, irrespectively of the clinical probability. These promising results require further confirmation in future trials.
Disclosures
Mahe: Leo Pharma: Research Funding, Speakers Bureau; BMS: Research Funding, Speakers Bureau; Bayer: Speakers Bureau; Pfizer: Speakers Bureau. Meyer:BMS-Pfizer: Other: travel support, Research Funding; Boehringer Ingelheim: Research Funding; LEO pharma: Other: travel support, Research Funding; SANOFI: Other: travel support, Research Funding; Bayer: Other: travel support. Contant:Diagnostica Stago: Employment. Depasse:Diagnostica Stago: Employment.
Giant cell tumor formation due to metallosis after open latarjet and partial shoulder resurfacing
